Loading
  • Pipeline Pipeline
    • Pipeline Chart
    • Validive
      • Overview
      • Severe Oral Mucositis and Oropharyngeal Cancer
      • Phase 2 Data Supports Further Development in OPC
      • MNPR-301-001 Clinical Trial
    • Camsirubicin
      • Overview
      • Clinical Data
      • Development Strategy
      • MNPR-201-001 Clinical Trial
    • MNPR-101 RIT & MNPR-101-Zr
    • MNPR-101
      • Overview
      • Development Strategy
    • MNPR-202
    • Collaborations
      • Overview
      • Current Collaborations
    • Intellectual Property
    • Publications
      • Validive
      • Camsirubicin
      • MNPR-101
  • Investors Investors
    • Overview
    • Annual Meeting
    • News / Events
      • Press Releases
      • IR Calendar
      • In the News
      • Email Alerts
    • Company Information
      • Profile
      • Presentations
      • Our Team
      • FAQ
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Our Team Our Team
  • Contact Us Contact Us
  • SIV Materials SIV Materials
  • Home
  • Investors
  • News / Events
  • Press Releases
Investors

Investors

  • Overview
  • Annual Meeting
  • News / Events
    • Press Releases
    • IR Calendar
    • In the News
    • Email Alerts
  • Company Info
    • Profile
    • Presentations
    • Our Team
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Press Releases
  • IR Calendar
  • In the News
  • Email Alerts

Press Releases

Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations

Feb 18, 2021

Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)

Feb 16, 2021

Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer

Feb 11, 2021

Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada

Feb 9, 2021

Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs

Dec 22, 2020

Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19

Dec 10, 2020

Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)

Dec 8, 2020

Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update

Nov 12, 2020

Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive®

Nov 9, 2020

Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020

Sep 14, 2020
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • About
    • Pipeline
    • Investors
    • Our Team
    • Contact Us
    • SIV Materials
    • Pipeline
    • Pipeline Chart
    • Validive
    • Camsirubicin
    • MNPR-101 RIT & MNPR-101-Zr
    • MNPR-101
    • MNPR-202
    • Collaborations
    • Intellectual Property
    • Publications
    • Investors
    • Overview
    • Annual Meeting
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance

    Terms and Conditions of Use

    © 2023 Monopar Therapeutics Inc. All Rights Reserved.